IP Library › Granted Patent US 7,687,521
Granted Patent B2
US 7,687,521 · App. 12/406,283 · Granted Mar 30, 2010

Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity

Assignee: Theravance, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,687,521
App. No.
12/406,283
Granted
Mar 30, 2010
Kind
B2
Abstract

This invention relates to compounds of formula I: wherein R 1 and R 2 are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions and combinations comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compound to, for example, treat pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.

Claims (20)

1. A method of producing bronchodilation in a mammal, the method comprising administering to the mammal a bronchodilation-producing amount of a compound of formula I:

wherein R 1 is methyl or ethyl; R 2 is methyl or ethyl; or a pharmaceutically acceptable salt or stereoisomer thereof.

2. The method of claim 1 , wherein the compound has formula II:

wherein R 1 is methyl or ethyl; R 2 is methyl or ethyl; or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 , wherein the compound has formula IIa:

or a pharmaceutically acceptable salt thereof.

4. The method of claim 3 , wherein the compound or the salt thereof is administered by inhalation.

5. The method of claim 3 , wherein the compound or the salt thereof is in micronized form.

6. A method of treating chronic obstructive pulmonary disease in a patient, the method comprising administering to the patient a compound of formula I:

wherein R 1 is methyl or ethyl; R 2 is methyl or ethyl; or a pharmaceutically acceptable salt or stereoisomer thereof.

7. The method of claim 6 , wherein the compound has formula II:

wherein R 1 is methyl or ethyl; R 2 is methyl or ethyl; or a pharmaceutically acceptable salt thereof.

8. The method of claim 6 , wherein the compound has formula IIa:

or a pharmaceutically acceptable salt thereof.

9. A method of treating asthma in a patient, the method comprising administering to the patient a compound of formula I:

wherein R 1 is methyl or ethyl; R 2 is methyl or ethyl; or a pharmaceutically acceptable salt or stereoisomer thereof.

10. The method of claim 9 , wherein the compound has formula II:

wherein R 1 is methyl or ethyl; R 2 is methyl or ethyl; or a pharmaceutically acceptable salt thereof.

11. The method of claim 9 , wherein the compound has formula IIa:

or a pharmaceutically acceptable salt thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2020
From: THERAVANCE RESPIRATORY COMPANY, LLC
To: THERAVANCE BIOPHARMA R&D IP, LLC
Reel/Frame 054393/0695 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2014
From: THERAVANCE, INC.
To: THERAVANCE RESPIRATORY COMPANY, LLC
Reel/Frame 033175/0553 →
Continuity (3)
Division 1178930000 · Apr 24, 2007
Provisional Application 6079470200 · Apr 25, 2006
Related Publication 20090176833A1 · Jul 9, 2009